Letter to the editor regarding "At Birth, Tales of Joy and Heartbreak"
By Marcy Darnovsky,
New York Times
| 10. 14. 2009
To the Editor:
“The Gift of Life, and Its Price” reports that the fertility industry’s professional organization encourages its members to transfer fewer embryos, so as to produce fewer multiple pregnancies and premature babies. The organization, the American Society for Reproductive Medicine, is to be commended for these efforts.
But its guidelines are routinely flouted. The society could put teeth behind its rules by publicly suspending the memberships of fertility practices in noncompliance. And it has resisted calls for public regulation and oversight.
Recent experiences with the financial sector have dramatized the dangers of inadequate public policy. The fertility industry, too, demonstrates the limits of self-regulation. Public regulation must be carefully written and not used to advance other agendas like opposition to reproductive rights. It’s past time for the federal government to set rules for the fertility industry and establish ways to enforce them.
Marcy Darnovsky
Berkeley, Calif., Oct. 11, 2009
The writer is associate executive director of the Center for Genetics and Society.
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...